All In Biotech

Drug Trial Radar · NCT07138274

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 19, 2026

Primary completion

Jun 2031

Study completion Dec 2031

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.

Conditions

  • Mild Autonomous Cortisol Secretion (MACS)
  • Autonomous Cortisol Secretion (ACS)

Interventions

  • Metyrapone 250 mg Oral TabletsDrug

    Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg

  • PlaceboDrug

    Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glucocorticoid to androgen ratioTime frame: 3 and 6 months
  2. Delta salivary cortisoneTime frame: 3 and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.